Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)

Abstract

TAC appears to be cost-effective in the management of early breast cancer in Korea.

The Cost–Utility of Adjuvant Chemotherapy Using Docetaxel and Cyclophosphamide Compared with Doxorubicin and Cyclophosphamide in Breast Cancer

“…Economic evaluations for other docetaxel-based adjuvant chemotherapy regimens for breast cancer have also been conducted 23,[42][43][44][45][46] . Compared with fac (5-fluorouracil-doxorubicin-cyclophosphamide), tac (docetaxel-doxorubicin-cyclophosphamide) administered with and without prophylactic g-csf was found to be a cost-effective strategy in a number of jurisdictions 36,37,39,40 .…”

Cost-effective analyses in Breast Cancer Research and Treatment

“…This concern has led to an entirely new field of research: analysis of cost effectiveness in medicine in general and oncology specifically [3]. BCRT has, like many journals with clinical content, included manuscripts in which the cost effectiveness of a new treatment has been compared to an existing one [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]. Recently, though, the Editors have noticed a disturbing trend in that the submitted manuscripts appear to have been mainly or totally prepared and written by pharmaceutical companies.…”

Economic burden of patients with inoperable advanced breast cancer receiving early or late capecitabine or trastuzumab as second-line treatment: A population-based study

“…However, few studies have focused on the economic burden of IABC, probably because the IABC population is smaller than that of operable ABC. Patients with IABC may require several conventional cytotoxic treatments, and if these treatments fail, the patients may receive targeted therapies, which further increased their economic burden [12][13][14] .…”